Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/ ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Discover the latest findings on transplantation outcomes in Myelodysplastic Syndrome and Acute Myeloid Leukaemia from EBMT ...

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the ...

MNV-201 is Minovia's second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatric Designation granted MNV-2 ...

Myelodysplastic syndromes (MDS) is a group of blood cancers. Red and white blood cells and platelets start as immature blood stem cells. In MDS, your blood stem cells do not mature into full ...